Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2015 - 2026)

Arbutus Biopharma (ABUS) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $11000.0 the latest figure, recorded in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 96.67% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33000.0 (down 96.77% YoY) and the FY2025 annual result came in at $400000.0, down 71.43% from the prior year.
• Depreciation & Amortization (CF) held at $11000.0 in Q1 2026 per ABUS's latest filing, from $11000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for ABUS reached as high as $394000.0 in Q1 2022 and fell as low as $11000.0 in Q2 2025.
• A 5-year average of $275000.0 and a median of $342000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) climbed 7.58% — and 2025, when it plunged 96.91%.
• Year by year, Depreciation & Amortization (CF) stood at $343000.0 in 2022, then gained by 7.58% to $369000.0 in 2023, then retreated by 8.94% to $336000.0 in 2024, then sank by 96.73% to $11000.0 in 2025, then changed by 0.0% to $11000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $11000.0, $11000.0, and $11000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.